Ignite Creation Date:
2024-07-17 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06473961
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-06-18
Brief Title:
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC
Sponsor:
Shanghai Juncell Therapeutics
Organization:
Shanghai Juncell Therapeutics
Study Overview
Official Title:
An Open Single-armed Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Non-Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MIZAR-005
Brief Summary:
20 participants are expected to be enrolled for the Phase Ib clinical trialthis trail is expected to be finished in 36 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None